Remodelling and Treatment of the Blood-Brain Barrier in Glioma

References

• Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–185. doi:10.1124/pr.57.2.415914466
   PubMed Web of Science ®Google Scholar
• Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21–78. doi:10.1152/physrev.00050.201730280653
   PubMed Web of Science ®Google Scholar
• Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17(9):564–580. doi:10.1038/nrm.2016.8027353478
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53. doi:10.1038/nrn182416371949
   PubMed Web of Science ®Google Scholar
• Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(7):1139–1151. doi:10.1038/jcbfm.2011.19722252235
   PubMed Web of Science ®Google Scholar
• Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. doi:10.1101/cshperspect.a02041225561720
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Routhe LJ, Moos T. The vascular basement membrane in the healthy and pathological brain. J Cereb Blood Flow Metab. 2017;37(10):3300–3317. doi:10.1177/0271678X1772243628753105
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584–1596. doi:10.1038/nm.340724309662
   PubMed Web of Science ®Google Scholar
• Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K. The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med. 2012;33(5–6):579–589. doi:10.1016/j.mam.2012.02.00322387049
   PubMed Web of Science ®Google Scholar
• Obermeier B, Verma A, Ransohoff RM. The blood-brain barrier. Handb Clin Neurol. 2016;133:39–59.27112670
   PubMedGoogle Scholar
• van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12. doi:10.1016/j.drup.2015.02.00225791797
   PubMed Web of Science ®Google Scholar
• Watkins S, Robel S, Kimbrough IF, Robert SM, Ellis-Davies G, Sontheimer H. Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells. Nat Commun. 2014;5:4196. doi:10.1038/ncomms519624943270
   PubMed Web of Science ®Google Scholar
• Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia. 2006;53(8):799–808. doi:10.1002/glia.2033416541395
   PubMed Web of Science ®Google Scholar
• Cuddapah VA, Robel S, Watkins S, Sontheimer H. A neurocentric perspective on glioma invasion. Nat Rev Neurosci. 2014;15(7):455–465. doi:10.1038/nrn376524946761
   PubMed Web of Science ®Google Scholar
• Montana V, Sontheimer H. Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci. 2011;31(13):4858–4867. doi:10.1523/JNEUROSCI.3825-10.201121451024
   PubMed Web of Science ®Google Scholar
• Zagzag D, Amirnovin R, Greco MA, et al. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest. 2000;80(6):837–849. doi:10.1038/labinvest.378008810879735
   PubMed Web of Science ®Google Scholar
• Winkler F, Kienast Y, Fuhrmann M, et al. Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia. 2009;57(12):1306–1315. doi:10.1002/glia.2085019191326
   PubMed Web of Science ®Google Scholar
• Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci. 2011;14(11):1398–1405. doi:10.1038/nn.294622030551
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25. doi:10.1016/j.nbd.2009.07.03019664713
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat. 2002;200(6):629–638. doi:10.1046/j.1469-7580.2002.00064.x12162730
   PubMed Web of Science ®Google Scholar
• Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610–622. doi:10.1038/nrn217517643088
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843–845. doi:10.1038/359843a01279431
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723–738. doi:10.1038/nrn311422048062
   PubMed Web of Science ®Google Scholar
• Pacioni S, D’Alessandris QG, Buccarelli M, et al. Brain invasion along perivascular spaces by glioma cells: relationship with blood-brain barrier. Cancers (Basel). 2019;12(1):18. doi:10.3390/cancers12010018
   PubMed Web of Science ®Google Scholar
• Worthmann H, Tryc AB, Goldbecker A, et al. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc Dis. 2010;30(1):85–92. doi:10.1159/00031462420484906
   PubMed Web of Science ®Google Scholar
• Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84(3):869–901. doi:10.1152/physrev.00035.200315269339
   PubMed Web of Science ®Google Scholar
• Markelc B, Bellard E, Sersa G, et al. Increased permeability of blood vessels after reversible electroporation is facilitated by alterations in endothelial cell-to-cell junctions. J Control Release. 2018;276:30–41. doi:10.1016/j.jconrel.2018.02.03229476881
   PubMed Web of Science ®Google Scholar
• Saitou M, Furuse M, Sasaki H, et al. Complex phenotype of mice lacking occludin, a component of tight junction strands. Mol Biol Cell. 2000;11(12):4131–4142. doi:10.1091/mbc.11.12.413111102513
   PubMed Web of Science ®Google Scholar
• Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev. 2010;64(2):328–363.20685221
   PubMed Web of Science ®Google Scholar
• Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161(3):653–660. doi:10.1083/jcb.20030207012743111
   PubMed Web of Science ®Google Scholar
• Guo J, Cai H, Zheng J, et al. Long non-coding RNA NEAT1 regulates permeability of the blood-tumor barrier via miR-181d-5p-mediated expression changes in ZO-1, occludin, and claudin-5. Biochim Biophys Acta Mol Basis Dis. 2017;1863(9):2240–2254. doi:10.1016/j.bbadis.2017.02.00528185956
   PubMed Web of Science ®Google Scholar
• Zhao L, Wang P, Liu Y, Ma J, Xue Y. miR-34c regulates the permeability of blood-tumor barrier via MAZ-mediated expression changes of ZO-1, occludin, and claudin-5. J Cell Physiol. 2015;230(3):716–731. doi:10.1002/jcp.2479925201524
   PubMed Web of Science ®Google Scholar
• Miao YS, Zhao YY, Zhao LN, et al. MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5. Cell Signal. 2015;27(1):156–167. doi:10.1016/j.cellsig.2014.10.00825452107
   PubMed Web of Science ®Google Scholar
• Erickson KK, Sundstrom JM, Antonetti DA. Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis. 2007;10(2):103–117. doi:10.1007/s10456-007-9067-z17340211
   PubMedGoogle Scholar
• Liu W, Wang P, Shang C, et al. Endophilin-1 regulates blood-brain barrier permeability by controlling ZO-1 and occludin expression via the EGFR-ERK1/2 pathway. Brain Res. 2014;1573:17–26. doi:10.1016/j.brainres.2014.05.02224854121
   PubMed Web of Science ®Google Scholar
• Chen L, Liu W, Wang P, et al. Endophilin-1 regulates blood-brain barrier permeability via EGFR-JNK signaling pathway. Brain Res. 2015;1606:44–53. doi:10.1016/j.brainres.2015.02.03225721793
   PubMed Web of Science ®Google Scholar
• Yang S, Jin H, Zhao Z. An ECV304 monoculture model for permeability assessment of blood-brain barrier. Neurol Res. 2018;40(2):117–121. doi:10.1080/01616412.2017.139888229100486
   PubMed Web of Science ®Google Scholar
• Neuhaus W, Wirth M, Plattner VE, Germann B, Gabor F, Noe CR. Expression of Claudin-1, Claudin-3 and Claudin-5 in human blood-brain barrier mimicking cell line ECV304 is inducible by glioma-conditioned media. Neurosci Lett. 2008;446(2–3):59–64. doi:10.1016/j.neulet.2008.09.02518817843
   PubMed Web of Science ®Google Scholar
• Neuhaus W, Germann B, Plattner VE, Gabor F, Wirth M, Noe CR. Alteration of the glycocalyx of two blood-brain barrier mimicking cell lines is inducible by glioma conditioned media. Brain Res. 2009;1279:82–89. doi:10.1016/j.brainres.2009.05.01019445905
   PubMed Web of Science ®Google Scholar
• Lin M, Zhu L, Wang J, Xue Y, Shang X. miR-424-5p maybe regulate blood-brain barrier permeability in a model in vitro with Abeta incubated endothelial cells. Biochem Biophys Res Commun. 2019;517(3):525–531. doi:10.1016/j.bbrc.2019.07.07531375213
   PubMed Web of Science ®Google Scholar
• Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100(3):323–331. doi:10.1007/s00401000018010965803
   PubMed Web of Science ®Google Scholar
• Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. 2010;10(10):712–723. doi:10.1038/nri285220865019
   PubMed Web of Science ®Google Scholar
• Wu C, Ivars F, Anderson P, et al. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med. 2009;15(5):519–527. doi:10.1038/nm.195719396173
   PubMed Web of Science ®Google Scholar
• Song J, Zhang X, Buscher K, et al. Endothelial basement membrane laminin 511 contributes to endothelial junctional tightness and thereby inhibits leukocyte transmigration. Cell Rep. 2017;18(5):1256–1269. doi:10.1016/j.celrep.2016.12.09228147279
   PubMed Web of Science ®Google Scholar
• Savettieri G, Di Liegro I, Catania C, et al. Neurons and ECM regulate occludin localization in brain endothelial cells. Neuroreport. 2000;11(5):1081–1084. doi:10.1097/00001756-200004070-0003510790886
   PubMed Web of Science ®Google Scholar
• Yao Y, Chen ZL, Norris EH, Strickland S. Astrocytic laminin regulates pericyte differentiation and maintains blood brain barrier integrity. Nat Commun. 2014;5(1):3413. doi:10.1038/ncomms441324583950
   PubMed Web of Science ®Google Scholar
• Xhima K, Weber-Adrian D, Silburt J. Glutamate induces blood-brain barrier permeability through activation of N-Methyl-D-Aspartate receptors. J Neurosci. 2016;36(49):12296–12298. doi:10.1523/JNEUROSCI.2962-16.201627927949
   PubMed Web of Science ®Google Scholar
• Vazana U, Veksler R, Pell GS, et al. Glutamate-mediated blood-brain barrier opening: implications for neuroprotection and drug delivery. J Neurosci. 2016;36(29):7727–7739. doi:10.1523/JNEUROSCI.0587-16.201627445149
   PubMed Web of Science ®Google Scholar
• Mendes B, Marques C, Carvalho I, et al. Influence of glioma cells on a new co-culture in vitro blood-brain barrier model for characterization and validation of permeability. Int J Pharm. 2015;490(1–2):94–101. doi:10.1016/j.ijpharm.2015.05.02725981617
   PubMed Web of Science ®Google Scholar
• Shimizu F, Sano Y, Maeda T, et al. Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. J Cell Physiol. 2008;217(2):388–399. doi:10.1002/jcp.2150818543246
   PubMed Web of Science ®Google Scholar
• Sa-Pereira I, Brites D, Brito MA. Neurovascular unit: a focus on pericytes. Mol Neurobiol. 2012;45(2):327–347. doi:10.1007/s12035-012-8244-222371274
   PubMed Web of Science ®Google Scholar
• Kim JA, Tran ND, Li Z, Yang F, Zhou W, Fisher MJ. Brain endothelial hemostasis regulation by pericytes. J Cereb Blood Flow Metab. 2006;26(2):209–217. doi:10.1038/sj.jcbfm.960018116015279
   PubMed Web of Science ®Google Scholar
• Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557–561. doi:10.1038/nature0952220944627
   PubMed Web of Science ®Google Scholar
• Bernacki J, Dobrowolska A, Nierwinska K, Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep. 2008;60(5):600–622.19066407
   PubMed Web of Science ®Google Scholar
• Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68(3):409–427. doi:10.1016/j.neuron.2010.09.04321040844
   PubMed Web of Science ®Google Scholar
• Wang Y, Pan L, Moens CB, Appel B. Notch3 establishes brain vascular integrity by regulating pericyte number. Development. 2014;141(2):307–317. doi:10.1242/dev.09610724306108
   PubMed Web of Science ®Google Scholar
• Caspani EM, Crossley PH, Redondo-Garcia C, Martinez S. Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes. PLoS One. 2014;9(7):e101402. doi:10.1371/journal.pone.010140225032689
   PubMed Web of Science ®Google Scholar
• Engelhardt S, Patkar S, Ogunshola OO. Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia. Br J Pharmacol. 2014;171(5):1210–1230.24641185
   PubMed Web of Science ®Google Scholar
• Jackson S, ElAli A, Virgintino D, Gilbert MR. Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer’s disease. Neuro-Oncology. 2017;19(9):1173–1182. doi:10.1093/neuonc/nox05828541444
   PubMed Web of Science ®Google Scholar
• Shimizu F, Sano Y, Saito K, et al. Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier. Neurochem Res. 2012;37(2):401–409. doi:10.1007/s11064-011-0626-822002662
   PubMed Web of Science ®Google Scholar
• Yi D, Xiang W, Zhang Q, et al. Human glioblastoma-derived mesenchymal stem cell to pericytes transition and angiogenic capacity in glioblastoma microenvironment. Cell Physiol Biochem. 2018;46(1):279–290. doi:10.1159/00048842929590646
   PubMedGoogle Scholar
• Zhang Q, Yi DY, Xue BZ, et al. CD90 determined two subpopulations of glioma-associated mesenchymal stem cells with different roles in tumour progression. Cell Death Dis. 2018;9(11):1101. doi:10.1038/s41419-018-1140-630368520
   PubMed Web of Science ®Google Scholar
• Maugeri R, Schiera G, Di Liegro CM, Fricano A, Iacopino DG, Di Liegro I. Aquaporins and brain tumors. Int J Mol Sci. 2016;17(7):1029. doi:10.3390/ijms17071029
   PubMed Web of Science ®Google Scholar
• Stokum JA, Kurland DB, Gerzanich V, Simard JM. Mechanisms of astrocyte-mediated cerebral edema. Neurochem Res. 2015;40(2):317–328. doi:10.1007/s11064-014-1374-324996934
   PubMed Web of Science ®Google Scholar
• Warth A, Kroger S, Wolburg H. Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae. Acta Neuropathol. 2004;107(4):311–318. doi:10.1007/s00401-003-0812-014735305
   PubMed Web of Science ®Google Scholar
• Noell S, Fallier-Becker P, Beyer C, Kroger S, Mack AF, Wolburg H. Effects of agrin on the expression and distribution of the water channel protein aquaporin-4 and volume regulation in cultured astrocytes. Eur J Neurosci. 2007;26(8):2109–2118. doi:10.1111/j.1460-9568.2007.05850.x17927773
   PubMed Web of Science ®Google Scholar
• Noell S, Fallier-Becker P, Deutsch U, Mack AF, Wolburg H. Agrin defines polarized distribution of orthogonal arrays of particles in astrocytes. Cell Tissue Res. 2009;337(2):185–195. doi:10.1007/s00441-009-0812-z19449033
   PubMed Web of Science ®Google Scholar
• Zhou J, Kong H, Hua X, Xiao M, Ding J, Hu G. Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport. 2008;19(1):1–5. doi:10.1097/WNR.0b013e3282f2b4eb18281883
   PubMed Web of Science ®Google Scholar
• Saadoun S, Tait MJ, Reza A, et al. AQP4 gene deletion in mice does not alter blood-brain barrier integrity or brain morphology. Neuroscience. 2009;161(3):764–772. doi:10.1016/j.neuroscience.2009.03.06919345723
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu K, Liu Y, et al. Increased cerebral vascularization and decreased water exchange across the blood-brain barrier in aquaporin-4 knockout mice. PLoS One. 2019;14(6):e0218415. doi:10.1371/journal.pone.021841531220136
   PubMed Web of Science ®Google Scholar
• Parat M-O, Riggins GJ. Caveolin-1, caveolae, and glioblastoma. Neuro-Oncology. 2012;14(6):679–688. doi:10.1093/neuonc/nos07922508761
   PubMed Web of Science ®Google Scholar
• Cassoni P, Senetta R, Castellano I, et al. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol. 2007;31(5):760–769. doi:10.1097/01.pas.0000213433.14740.5d17460461
   PubMed Web of Science ®Google Scholar
• Ronaldson PT, Bendayan M, Gingras D, Piquette-Miller M, Bendayan R. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J Neurochem. 2004;89(3):788–800. doi:10.1111/j.1471-4159.2004.02417.x15086534
   PubMed Web of Science ®Google Scholar
• Machein MR, Kullmer J, Fiebich BL, Plate KH, Warnke PC. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery. 1999;44(4):732–740;discussion 740–731. doi:10.1097/00006123-199904000-00022
   PubMed Web of Science ®Google Scholar
• Cao Y, Sundgren PC, Tsien CI, Chenevert TT, Junck L. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol. 2006;24(8):1228–1235. doi:10.1200/JCO.2005.04.723316525177
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Hu LS, Parney IF, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology. 2018;20(2):184–191. doi:10.1093/neuonc/nox17529016900
   PubMed Web of Science ®Google Scholar
• Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9(9):906–920. doi:10.1016/S1474-4422(10)70181-220705518
   PubMed Web of Science ®Google Scholar
• Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010;255(2):415–425. doi:10.1148/radiol.1009069920413754
   PubMed Web of Science ®Google Scholar
• Ma J, Wang P, Liu Y, Zhao L, Li Z, Xue Y. Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5. J Cell Physiol. 2014;229(7):916–926. doi:10.1002/jcp.2452324318462
   PubMed Web of Science ®Google Scholar
• Hersh DS, Wadajkar AS, Roberts N, et al. Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des. 2016;22(9):1177–1193. doi:10.2174/138161282266615122115073326685681
   PubMed Web of Science ®Google Scholar
• Emerich DF, Dean RL, Osborn C, Bartus RT. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet. 2001;40(2):105–123. doi:10.2165/00003088-200140020-0000311286321
   PubMed Web of Science ®Google Scholar
• Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev. 2011;63(1):1–34. doi:10.1124/pr.110.00328521303899
   PubMed Web of Science ®Google Scholar
• Kim DG, Bynoe MS. A2A adenosine receptor regulates the human blood-brain barrier permeability. Mol Neurobiol. 2015;52(1):664–678. doi:10.1007/s12035-014-8879-225262373
   PubMed Web of Science ®Google Scholar
• Bynoe MS, Viret C, Yan A, Kim DG. Adenosine receptor signaling: a key to opening the blood-brain door. Fluids Barriers CNS. 2015;12(1):20. doi:10.1186/s12987-015-0017-726330053
   PubMedGoogle Scholar
• Wu J, Zhao D, Wu S, Wang D. Ang-(1-7) exerts protective role in blood-brain barrier damage by the balance of TIMP-1/MMP-9. Eur J Pharmacol. 2015;748:30–36. doi:10.1016/j.ejphar.2014.12.00725523481
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Xie J, Liang B, Wu J. Suppression of angiotensin-(1-7) on the disruption of blood-brain barrier in rat of brain glioma. Pathol Oncol Res. 2019;25(1):429–435. doi:10.1007/s12253-018-0471-z30229380
   PubMed Web of Science ®Google Scholar
• Zhou W, Chen C, Shi Y, et al. Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy. Cell Stem Cell. 2017;21(5):591–603 e594. doi:10.1016/j.stem.2017.10.00229100012
   PubMed Web of Science ®Google Scholar
• Alvarez JI, Dodelet-Devillers A, Kebir H, et al. The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science. 2011;334(6063):1727–1731. doi:10.1126/science.120693622144466
   PubMed Web of Science ®Google Scholar
• Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci U S A. 2009;106(6):1977–1982. doi:10.1073/pnas.080869810619174516
   PubMed Web of Science ®Google Scholar
• Wen L, Tan Y, Dai S, et al. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy. Drug Deliv. 2017;24(1):1843–1855. doi:10.1080/10717544.2017.138673129182025
   PubMed Web of Science ®Google Scholar
• Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol. 2017;133(3):455–467. doi:10.1007/s11060-017-2477-x28527008
   PubMed Web of Science ®Google Scholar
• Fan CH, Lin WH, Ting CY, et al. Contrast-enhanced ultrasound imaging for the detection of focused ultrasound-induced blood-brain barrier opening. Theranostics. 2014;4(10):1014–1025. doi:10.7150/thno.957525161701
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu H, Du X, et al. Increasing of blood-brain tumor barrier permeability through transcellular and paracellular pathways by microbubble-enhanced diagnostic ultrasound in a C6 glioma model. Front Neurosci. 2017;11:86. doi:10.3389/fnins.2017.0008628280455
   PubMed Web of Science ®Google Scholar
• Meng Y, Pople CB, Lea-Banks H, et al. Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies. J Control Release. 2019;309:25–36. doi:10.1016/j.jconrel.2019.07.02331326464
   PubMed Web of Science ®Google Scholar
• Chen P-Y, Hsieh H-Y, Huang C-Y, Lin C-Y, Wei K-C, Liu H-L. Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study. J Transl Med. 2015;13:93. doi:10.1186/s12967-015-0451-y25784614
   PubMed Web of Science ®Google Scholar
• Ting C-Y, Fan C-H, Liu H-L, et al. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials. 2012;33(2):704–712. doi:10.1016/j.biomaterials.2011.09.09622019122
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xia C, Xue Y, Liu Y. Synergistic effect of low-frequency ultrasound and low-dose bradykinin on increasing permeability of the blood-tumor barrier by opening tight junction. J Neurosci Res. 2009;87(10):2282–2289. doi:10.1002/jnr.2206119326437
   PubMed Web of Science ®Google Scholar
• Wang JE, Liu YH, Liu LB, Xia CY, Zhang Z, Xue YX. Effects of combining low frequency ultrasound irradiation with papaverine on the permeability of the blood-tumor barrier. J Neurooncol. 2011;102(2):213–224. doi:10.1007/s11060-010-0321-720683758
   PubMed Web of Science ®Google Scholar
• Jue TR, McDonald KL. The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol. 2016;127(3):427–434. doi:10.1007/s11060-016-2080-626900075
   PubMed Web of Science ®Google Scholar
• Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70(3):412–445. doi:10.1124/pr.117.01494429669750
   PubMed Web of Science ®Google Scholar
• Chen L, Zeng D, Xu N, et al. Blood-brain barrier- and blood-brain tumor barrier-penetrating peptide-derived targeted therapeutics for glioma and malignant tumor brain metastases. ACS Appl Mater Interfaces. 2019;11(45):41889–41897. doi:10.1021/acsami.9b1404631615203
   PubMed Web of Science ®Google Scholar
• Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos. 2013;41(1):33–39. doi:10.1124/dmd.112.04832223014761
   PubMed Web of Science ®Google Scholar
• Zhao HF, Wang J, Shao W, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16(1):100. doi:10.1186/s12943-017-0670-328592260
   PubMed Web of Science ®Google Scholar
• Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117(2):333–345. doi:10.1111/j.1471-4159.2011.07208.x21291474
   PubMed Web of Science ®Google Scholar
• Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro-Oncology. 2016;18(1):27–36. doi:10.1093/neuonc/nov16426359209
   PubMed Web of Science ®Google Scholar
• Parrish KE, Sarkaria JN, Elmquist WF. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier. Clin Pharmacol Ther. 2015;97(4):336–346. doi:10.1002/cpt.7125669487
   PubMed Web of Science ®Google Scholar
• Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23–37. doi:10.1016/j.jconrel.2016.02.02626892752
   PubMed Web of Science ®Google Scholar
• Galstyan A, Markman JL, Shatalova ES, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019;10(1):3850. doi:10.1038/s41467-019-11719-331462642
   PubMed Web of Science ®Google Scholar
• Shi D, Mi G, Shen Y, Webster TJ. Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in vitro blood-brain barrier. Nanoscale. 2019;11(32):15057–15071. doi:10.1039/C9NR03931G31369016
   PubMed Web of Science ®Google Scholar
• Li X, Tsibouklis J, Weng T, et al. Nano carriers for drug transport across the blood-brain barrier. J Drug Target. 2017;25(1):17–28. doi:10.1080/1061186X.2016.118427227126681
   PubMed Web of Science ®Google Scholar
• Anders CK, Adamo B, Karginova O, et al. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One. 2013;8(5):e61359. doi:10.1371/journal.pone.006135923650496
   PubMed Web of Science ®Google Scholar
• Rehman M, Madni A, Shi D, et al. Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles. Nanoscale. 2017;9(40):15434–15440. doi:10.1039/C7NR05216B28976512
   PubMed Web of Science ®Google Scholar
• Mo J, He L, Ma B, Chen T. Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood-brain barrier. ACS Appl Mater Interfaces. 2016;8(11):6811–6825. doi:10.1021/acsami.5b1173026911360
   PubMed Web of Science ®Google Scholar
• Lin T, Zhao P, Jiang Y, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano. 2016;10(11):9999–10012. doi:10.1021/acsnano.6b0426827934069
   PubMed Web of Science ®Google Scholar
• Fan K, Jia X, Zhou M, et al. Ferritin nanocarrier traverses the blood brain barrier and kills glioma. ACS Nano. 2018;12(5):4105–4115. doi:10.1021/acsnano.7b0696929608290
   PubMed Web of Science ®Google Scholar
• Kumari S, Ahsan SM, Kumar JM, Kondapi AK, Rao NM. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep. 2017;7(1):6602. doi:10.1038/s41598-017-06888-428747713
   PubMed Web of Science ®Google Scholar
• Rufino-Ramos D, Albuquerque PR, Carmona V, Perfeito R, Nobre RJ, Pereira de Almeida L. Extracellular vesicles: novel promising delivery systems for therapy of brain diseases. J Control Release. 2017;262:247–258. doi:10.1016/j.jconrel.2017.07.00128687495
   PubMed Web of Science ®Google Scholar
• Kolter M, Ott M, Hauer C, Reimold I, Fricker G. Nanotoxicity of poly(n-butylcyano-acrylate) nanoparticles at the blood-brain barrier, in human whole blood and in vivo. J Control Release. 2015;197:165–179. doi:10.1016/j.jconrel.2014.11.00525445700
   PubMed Web of Science ®Google Scholar
• Tang J, Xiong L, Zhou G, et al. Silver nanoparticles crossing through and distribution in the blood-brain barrier in vitro. J Nanosci Nanotechnol. 2010;10(10):6313–6317. doi:10.1166/jnn.2010.262521137724
   PubMed Web of Science ®Google Scholar
• Tang W, Fan W, Lau J, Deng L, Shen Z, Chen X. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev. 2019;48(11):2967–3014. doi:10.1039/C8CS00805A31089607
   PubMed Web of Science ®Google Scholar